Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells
详细信息 查看全文
- 作者：Wenxing Chen ; Yanhong Pan ; Siliang Wang ; Yuping Liu ; Guangying Chen…
- 关键词：Cryptotanshinone ; AMPK ; TSC2 ; mTORC1
- 刊名：BMC Cancer
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：17
- 期：1
- 全文大小：2591KB
- 刊物主题：Cancer Research; Oncology; Surgical Oncology; Health Promotion and Disease Prevention; Biomedicine, general; Medicine/Public Health, general;
- 出版者：BioMed Central
- ISSN：1471-2407
- 卷排序：17
文摘
BackgroundCryptotanshinone (CPT), a fat-soluble phenanthraquinone from Salvia miltiorrhiza Bunge, has been demonstrated to inhibit phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), a couple of direct downstream effectors of the mammalian target of rapamycin complex 1 (mTORC1), resulting in cancer cell arrested in G0 phase and subsequent inhibition of proliferation. However, its concrete molecular mechanism about how CPT inhibits mTORC1 signaling pathway is unclear.